CoreAge Rx 4Play

Identify the proposed preparation

CoreAge describes 4Play as containing apomorphine, sildenafil, tadalafil and vardenafil. Its product information lists 2 mg, 40 mg, 4 mg and 7.5 mg respectively per 2 mL. These are the advertised formulation details, not a recommendation about how much a reader should take. [Product information]

The product page calls it an oral suspension, while the offer uses sublingual-solution language. Ask the prescribing clinician and dispensing pharmacist to confirm the supplied form, route and directions. Do not decide that distinction from the name alone.

Read the pack as a purchase description

The offer advertises five bottles totaling 10 mL for $114, described as a one-month pack. It says assessment and shipping are included, with a charge only if prescribed and optional automatic refills after the first purchase. A commercial pack description does not establish an individual use frequency. Confirm the selected terms and any future processing date. [Offer]

Ask about the evidence for this combination

FDA does not approve compounded drugs. Approval or study of an ingredient does not establish the safety, effectiveness, onset or duration of this particular combination. The Viagra label also says combining it with other PDE5 inhibitors or ED therapies is not recommended. Those issues belong in the prescribing discussion rather than disappearing behind a multi-ingredient headline. [FDA] [Label]

Ask why the preparation is being proposed, what approved alternatives were considered and how a concern after dispensing would be handled. Our identity and approval guide helps organize those questions.

Understand what first placement means

4Play receives sponsored first placement here; links may generate compensation. We have not tested the preparation, enrolled as patients or measured outcomes. Placement does not establish clinical superiority. Use the care-pathway overview to examine other arrangements and the order guide to clarify the transaction.